keyword
MENU ▼
Read by QxMD icon Read
search

Intravitreal implant

keyword
https://www.readbyqxmd.com/read/27911446/treatment-patterns-of-ranibizumab-intravitreal-injection-and-dexamethasone-intravitreal-implant-for-retinal-vein-occlusion-in-the-usa
#1
S Nghiem-Buffet, S Baillif, S Regnier, A Skelly, N Yu, A Sodi
PurposeRanibizumab, an anti-vascular endothelial growth factor, and dexamethasone, a corticosteroid, have been shown to be effective in treating macular oedema secondary to retinal vein occlusion (RVO) (central RVO (CRVO) and branch RVO (BRVO)). Their real-world usage, however, has yet to be compared. We therefore evaluated ophthalmology visits for both drugs using US patient-level data.MethodsThe IMS Health Real-World Data Medical Claims database was used to identify treatment-naive patients receiving ranibizumab intravitreal injections or dexamethasone intravitreal implants between June 2010 and February 2014 who had 12 months of follow-up data...
December 2, 2016: Eye
https://www.readbyqxmd.com/read/27906070/subretinal-adipose-tissue-derived-mesenchymal-stem-cell-implantation-in-advanced-stage-retinitis-pigmentosa-a-phase-i-clinical-safety-study
#2
Ayse Oner, Z Burcin Gonen, Neslihan Sinim, Mustafa Cetin, Yusuf Ozkul
BACKGROUND: This prospective clinical case series aimed to investigate the safety of subretinal adipose tissue-derived mesenchymal stem cell (ADMSC) implantation in advanced stage retinitis pigmentosa (RP). METHODS: This study included 11 patients with end-stage RP who received subretinal implantation of ADMSCs. All patients had a total visual field defect and five of them only had light perception. The best corrected visual acuity (BCVA) in the study was 20/2000...
December 1, 2016: Stem Cell Research & Therapy
https://www.readbyqxmd.com/read/27903073/comparison-between-early-or-late-intravitreal-injection-of-dexamethasone-implant-in-branch-brvo-or-central-crvo-retinal-vein-occlusion-six-months-follow-up
#3
Fernanda Pacella, Giuseppe La Torre, Stefania Basili, Monica Autolitano, Antonella Pascarella, Tommaso Lenzi, Elena Pacella
PURPOSE: The purpose of this study was to compare early and late injections of intravitreal dexamethasone implant in patients affected by central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) with a six-month follow-up. We assessed whether an earlier treatment start (within 7 days from diagnosis) could be more beneficial than a delayed (or late) treatment start (after 7 days). MATERIALS AND METHODS: The study included 81 patients (81 eyes) affected by retinal vein occlusion...
November 30, 2016: Cutaneous and Ocular Toxicology
https://www.readbyqxmd.com/read/27893624/prospective-evaluation-of-a-sustained-release-dexamethasone-intravitreal-implant-for-cystoid-macular-edema-in-quiescent-uveitis
#4
Rahul N Khurana, Alok S Bansal, Louis K Chang, James D Palmer, Chengqing Wu, Mark R Wieland
PURPOSE: To investigate dexamethasone intravitreal implant (DEX implant; OZURDEX, Allergan, Inc) in the treatment of uveitic cystoid macular edema that had persisted in the absence of intraocular inflammation. METHODS: In this prospective interventional case series, 10 patients with uveitic cystoid macular edema and quiescent uveitis were treated with dexamethasone intravitreal implant at baseline and evaluated monthly for one year. Patients were retreated whenever cystoid macular edema recurred...
November 23, 2016: Retina
https://www.readbyqxmd.com/read/27882244/evaluation-of-peripapillary-nerve-fiber-layer-after-dexamethasone-implantation-ozurdex-in-branch-retinal-vein-occlusions
#5
Muhammed Nurullah Bulut, Yusuf Özertürk, Ümit Çallı, Güzide Akçay, Ulviye Kıvrak, Kezban Bulut
Purpose. To evaluate the peripapillary retinal nerve fiber layer (RNFL) thicknesses of patients treated with intravitreal Ozurdex implant due to branch retinal vein occlusion (BRVO) related macular edema (ME). Methods. Thirty-three eyes of 33 patients treated with Ozurdex implant due to ME associated with BRVO were included in the study. Ophthalmic examinations including determination of best corrected visual acuity (BCVA), measurement of intraocular pressure (IOP), and central macular thickness (CMT) and peripapillary RNFL assessment with optical coherence tomography (OCT) were performed before the injection of Ozurdex implant and during the 6-month follow-up period after the injection...
2016: Journal of Ophthalmology
https://www.readbyqxmd.com/read/27878430/short-term-safety-of-dexamethasone-implant-for-treatment-of-macular-edema-due-to-retinal-vein-occlusion-in-eyes-with-glaucoma-or-treated-ocular-hypertension
#6
Sofia Theodoropoulou, Abdallah A Ellabban, Robert L Johnston, Helena Cilliers, Quresh Mohamed, Ahmed B Sallam
PURPOSE: To report the short-term safety of dexamethasone implants to treat macular edema due to retinal vein occlusion (RVO), in eyes with treated glaucoma or ocular hypertension at baseline using an as-needed re-treatment regimen. METHODS: Retrospective clinical database study from two centers using the same electronic medical record system. Extracted data included: intraocular pressure (IOP), visual acuity (VA), central 1 mm retinal thickness (CRT) by optical coherence tomography, phakic status, number of injections, glaucoma treatment, and peri-operative complications...
November 22, 2016: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/27870799/choroidal-thickness-changes-after-intravitreal-dexamethasone-implant-injection-for-the-treatment-of-macular-edema-due-to-retinal-vein-occlusion
#7
Ebru Esen, Selcuk Sizmaz, Nihal Demircan
PURPOSE: To investigate changes in choroidal thickness after intravitreal injection of a dexamethasone implant for macular edema due to retinal vein occlusion. METHODS: Thirty-one eyes of 31 patients, treated with a single dose of a dexamethasone implant for retinal vein occlusion-associated macular edema, were included. Subfoveal choroidal thickness (SFCT) and central macular thickness of the affected eyes were compared with those of the normal contralateral eyes at baseline and 1, 3, and 5 months after injection...
December 2016: Retina
https://www.readbyqxmd.com/read/27858937/intravitreal-dexamethasone-implant-for-recurrent-cystoid-macular-edema-due-to-irvine-gass-syndrome-a-prospective-case-series
#8
A Sudhalkar, J Chhablani, A Vasavada, D Bhojwani, V Vasavada, S Vasavada
PurposeTo determine the preliminary efficacy and safety of off-label dexamethasone implant for treatment of recurrent cystoid macular edema (CME) secondary to Irvine-Gass syndrome (IGS).Patients and methodsThis study was set in Raghudeep Eye Clinic, Ahmedabad and LV Prasad Eye Institute, Hyderabad (India). It is a Prospective Case Series. Prospective case series comprising of patients with uncomplicated pseudophakia and CME due to IGS who recurred after one course of topical steroids with NSAIDS and a sub-Tenon corticosteroid injection...
November 18, 2016: Eye
https://www.readbyqxmd.com/read/27829389/chronic-post-operative-iris-prosthesis-endophthalmitis-in-a-patient-with-traumatic-aniridia-a-case-report
#9
Kevin C Firl, Sandra R Montezuma
BACKGROUND: Post-operative endophthalmitis is a serious complication of intraocular surgery which may present acutely or chronically. Chronic post-operative endophthalmitis is characterized by decreased visual acuity, mild pain, and low-grade uveitis several weeks or months after intraocular surgery which may be responsive to corticosteroids, but recur upon tapering. Low virulence organisms such as Propionibacterium acnes are the most common culprit organisms, and treatment most often consists of both intravitreal antibiotic injections and surgery...
November 9, 2016: BMC Ophthalmology
https://www.readbyqxmd.com/read/27825329/intravitreal-dexamethasone-implants-for-the-treatment-of-refractory-scleritis-combined-with-uveitis-in-adult-onset-still-s-disease-a-case-report
#10
Seong Joon Ahn, Sun Jin Hwang, Byung Ro Lee
BACKGROUND: Adult-onset Still's disease is a systemic inflammatory disease which presents with uveitis and scleritis in the eye. Intravitreal dexamethasone implants are used for the treatment of refractory uveitis. CASE PRESENTATION: A 19-year-old woman diagnosed to have adult-onset Still's disease for fevers, joint pain, and a salmon-colored bumpy rash presented with scleritis and uveitis in the left eye. Topical and systemic steroids with oral methotrexate failed to control the inflammation...
November 8, 2016: BMC Ophthalmology
https://www.readbyqxmd.com/read/27815789/corticosteroids-and-anti-complement-therapy-in-retinal-diseases
#11
Raja Narayanan, Baruch D Kuppermann
Corticosteroids are unique in that they are the one class of agents that acts upon most of the multiple processes in the pathophysiology of macular edema. Corticosteroids are capable of inhibiting prostaglandin and leukotriene synthesis as well as interfering with intercellular adhesion molecule-1 (ICAM-1), interleukin-6, VEGF-A, and stromal cell derived factor-1 pathways. Triamcinolone, dexamethasone, and fluocinolone have been extensively used in the treatment of retinal and choroidal vascular diseases. Sustained release implants of steroids have reduced the burden of repeated intravitreal injections necessary in most of the retinal diseases...
November 5, 2016: Handbook of Experimental Pharmacology
https://www.readbyqxmd.com/read/27807930/human-bone-marrow-mesenchymal-stem-cells-for-retinal-vascular-injury
#12
Jin-Da Wang, Ying An, Jing-Shang Zhang, Xiu-Hua Wan, Jost B Jonas, Liang Xu, Wei Zhang
PURPOSE: To examine the potential of intravitreally implanted human bone marrow-derived mesenchymal stem cells (BMSCs) to affect vascular repair and the blood-retina barrier in mice and rats with oxygen-induced retinopathy, diabetic retinopathy or retinal ischaemia-reperfusion damage. METHODS: Three study groups (oxygen-induced retinopathy group: 18 C57BL/6J mice; diabetic retinopathy group: 15 rats; retinal ischaemia-reperfusion model: 18 rats) received BMSCs injected intravitreally...
November 3, 2016: Acta Ophthalmologica
https://www.readbyqxmd.com/read/27806001/ocular-hypertension-after-intravitreal-dexamethasone-ozurdex-sustained-release-implant
#13
Eric K Chin, David R P Almeida, Gabriel Velez, Kunyong Xu, Maria Peraire, Maria Corbella, Yasser M Elshatory, Young H Kwon, Karen M Gehrs, H Culver Boldt, Elliott H Sohn, Stephen R Russell, James C Folk, Vinit B Mahajan
PURPOSE: To evaluate ocular hypertension (OHT) after Ozurdex injection to determine the incidence of OHT, therapy for OHT, and any associative factors such as diagnosis, underlying glaucoma and therapy, or sequential Ozurdex injection(s). METHODS: Retrospective consecutive case series with patients receiving one or more intravitreal Ozurdex implantations at a tertiary care academic center. Ocular hypertension was defined as a single measurement of ≥30 mmHg or an increase of ≥10 mmHg from baseline...
November 1, 2016: Retina
https://www.readbyqxmd.com/read/27803875/dexamethasone-intravitreal-implant-for-diabetic-macular-edema-in-a-pregnant-patient
#14
Romi Yoo, Hyung Chan Kim, Hyewon Chung
No abstract text is available yet for this article.
2016: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/27803859/an-eighteen-month-follow-up-study-on-the-effects-of-intravitreal-dexamethasone-implant-in-diabetic-macular-edema-refractory-to-anti-vegf-therapy
#15
Fernanda Pacella, Maria Rosaria Romano, Paolo Turchetti, Giovanna Tarquini, Anna Carnovale, Antonella Mollicone, Alessandra Mastromatteo, Elena Pacella
AIM: To evaluate the long-term efficacy and safety of dexamethasone implants in subjects affected by diabetic macular edema (DME) resistant to anti-vascular endothelial growth factor (VEGF) therapy. METHODS: Thirty-two DME patients were enrolled. A 700 microgram slow release Intravitreal Dexamethasone Implant (Ozurdex(®)) was placed in the vitreous cavity. All patients were followed for 18mo. Best-corrected visual acuity (BCVA) measured with Early Treatment Diabetic Retinopathy Study (ETDRS) and central macular thickness (CMT) exams were carried out at baseline (T0) and after 1 (T1), 3 (T3), 4 (T4), 6 (T6), 9 (T9), 12 (T12), 15 (T15), and 18mo (T18) post injection...
2016: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/27800199/-magic-bullet-eccentric-macular-hole-as-a-complication-from-dexamethasone-implant-insertion
#16
Logan Christensen, Riley Sanders, Jeffrey Olson
Introduction. Intravitreal drug injections and implants are generally safe but do carry some risk, from both the procedure itself and adverse effects of the medications. We report a case of an eccentric macular hole after dexamethasone implant (Ozurdex®) administration. Ex vitro force testing was performed to evaluate dexamethasone implant injection force. Methods. Five dexamethasone implant (Ozurdex) applicators were placed 16 mm from a force plate and the force of the injected dexamethasone pellet was recorded in Newtons...
2016: Case Reports in Ophthalmological Medicine
https://www.readbyqxmd.com/read/27784291/retrospective-controlled-observational-case-study-of-patients-with-central-retinal-vein-occlusion-and-initially-low-visual-acuity-treated-with-an-intravitreal-dexamethasone-implant
#17
Sibylle Winterhalter, Gerrit Alexander Vom Brocke, Daniel Pilger, Annabelle Eckert, Juliane Schlomberg, Anne Rübsam, Matthias Karl Klamann, Enken Gundlach, Tina Dietrich-Ntoukas, Antonia Maria Joussen
BACKGROUND: Patients with initially low visual acuity were excluded from the therapy approval studies for retinal vein occlusion. But up to 28 % of patients presenting with central retinal vein occlusion have a baseline BCVA of less than 34 ETDRS letters (0.1). The purpose of our study was to assess visual acuity and central retinal thickness in patients suffering from central retinal vein occlusion and low visual acuity (<0.1) in comparison to patients with visual acuity (≥0.1) treated with Dexamethasone implant 0...
October 27, 2016: BMC Ophthalmology
https://www.readbyqxmd.com/read/27778454/quantification-of-fluid-resorption-from-diabetic-macular-oedema-with-foveal-serous-detachment-after-dexamethasone-intravitreal-implant-ozurdex-%C3%A2-in-a-pregnant-diabetic
#18
Delila Hodzic-Hadzibegovic, Shakoor Ba-Ali, Marianne Valerius, Henrik Lund-Andersen
PURPOSE: To quantify the fluid resorption from the centre of the fovea in a pregnant woman with diabetic macular oedema by daily optical coherence tomography (OCT) measurements after the administration of intravitreal dexamethasone implant (Ozurdex(®) ). METHODS: A 36-year-old pregnant woman with type 1 diabetes for 33 years presented with diabetic macular oedema with foveal serous detachment and symptomatic vision loss at 16 gestational weeks. Best-corrected visual acuity (BCVA) in Snellen notation and central retinal volume assessed by optical coherence tomography (OCT, Topcon Corporation) were measured almost on a daily basis the first five weeks after implantation and then 2-3 times per month until childbirth...
October 24, 2016: Acta Ophthalmologica
https://www.readbyqxmd.com/read/27768792/vision-related-quality-of-life-outcomes-in-the-bevordex-study-a-clinical-trial-comparing-ozurdex-sustained-release-dexamethasone-intravitreal-implant-and-bevacizumab-treatment-for-diabetic-macular-edema
#19
Christine Aroney, Samantha Fraser-Bell, Ecosse L Lamoureux, Mark C Gillies, Lyndell L Lim, Eva K Fenwick
Purpose: To determine the patient-centered effectiveness of treatment with the slow-release dexamethasone intravitreal implant (DEX implant) and intravitreal bevacizumab using the Impact of Vision Impairment Questionnaire (IVI), a vision-related quality of life (VRQoL) measure, in patients with visual impairment secondary to center-involving diabetic macular edema (DME). Methods: Patients with DME were enrolled in a phase 2, prospective, multicenter, randomized, single-masked clinical trial and received either DEX implant 4 monthly or bevacizumab monthly, both pro re nata...
October 1, 2016: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/27768641/safety-of-intravitreal-dexamethasone-implant-ozurdex-the-safodex-study-incidence-and-risk-factors-of-ocular-hypertension
#20
Ariane Malclès, Corinne Dot, Nicolas Voirin, Anne-Laure Vié, Émilie Agard, David Bellocq, Philippe Denis, Laurent Kodjikian
PURPOSE: To analyze the incidence, risk factors, and time course of intraocular pressure elevation after intravitreal dexamethasone implant (Ozurdex). METHODS: The medical charts of 421 consecutive eyes (361 patients) receiving one or more Ozurdex implant between October 2010 and February 2015 were reviewed retrospectively. Ocular hypertension was defined as intraocular pressure of at least 25 mmHg or an increase of at least 10 mmHg from baseline. The main indications for treatment were retinal vein occlusion (34%), diabetic macular edema (30%), postsurgical macular edema (17%), uveitis (14%), and other etiologies (5%)...
October 20, 2016: Retina
keyword
keyword
99632
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"